Back

Cost-effectiveness of risk-stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage

2025-06-12 health economics Title + abstract only
View on medRxiv
Show abstract

BackgroundCervical cancer screening in the Netherlands consists of human papillomavirus (HPV) testing followed by cytological triage at age 30, 35, 40, 50 and 60 years. Women are also invited at age 45, 55 and 65 years if they did not test HPV-negative five years earlier (risk-based invitation). With influx of birth cohorts vaccinated against HPV, de-intensification may be needed to maintain a cost-effective program. MethodsWe used an updated and recalibrated model of type-specific HPV transmis...

Predicted journal destinations